Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Nicholas Rebold; Taylor Morrisette; Abdalhamid M. Lagnf; Sara Alosaimy; Dana Holger; Katie Barber; Julie Ann Justo; Kayla Antosz; Travis J. Carlson; Jeremy J. Frens; Mark Biagi; Wesley D. Kufel; William J. Moore; Nicholas Mercuro; Brian R. Raux; Michael J. Rybak

doi:10.1093/ofid/ofab554

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Nicholas Rebold
, Taylor Morrisette
, Abdalhamid M. Lagnf
, Sara Alosaimy
, Dana Holger
, Katie Barber
, Julie Ann Justo
, Kayla Antosz
, Travis J. Carlson
, Jeremy J. Frens
, Mark Biagi
, Wesley D. Kufel
, William J. Moore
, Nicholas Mercuro
, Brian R. Raux
, Michael J. Rybak

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

Original language	English (US)
Article number	ofab554
Journal	Open Forum Infectious Diseases
Volume	8
Issue number	12
DOIs	https://doi.org/10.1093/ofid/ofab554
State	Published - Dec 1 2021
Externally published	Yes

Keywords

Pseudomonas aeruginosa
carbapenem-resistant Enterobacterales
imipenem-cilastatin-relebactam
multidrug-resistant

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofab554

Cite this

Rebold, N., Morrisette, T., Lagnf, A. M., Alosaimy, S., Holger, D., Barber, K., Justo, J. A., Antosz, K., Carlson, T. J., Frens, J. J., Biagi, M., Kufel, W. D., Moore, W. J., Mercuro, N., Raux, B. R., & Rybak, M. J. (2021). Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infectious Diseases, 8(12), Article ofab554. https://doi.org/10.1093/ofid/ofab554

Rebold, N, Morrisette, T, Lagnf, AM, Alosaimy, S, Holger, D, Barber, K, Justo, JA, Antosz, K, Carlson, TJ, Frens, JJ, Biagi, M, Kufel, WD, Moore, WJ, Mercuro, N, Raux, BR & Rybak, MJ 2021, 'Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections', Open Forum Infectious Diseases, vol. 8, no. 12, ofab554. https://doi.org/10.1093/ofid/ofab554

@article{5ae5ef3b7f0349b9b24b73d72d33a471,

title = "Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections",

abstract = "A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52\%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76\%), and 15/16 (94\%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67\%) patients. Two patients experienced adverse effects.",

keywords = "Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, imipenem-cilastatin-relebactam, multidrug-resistant",

author = "Nicholas Rebold and Taylor Morrisette and Lagnf, \{Abdalhamid M.\} and Sara Alosaimy and Dana Holger and Katie Barber and Justo, \{Julie Ann\} and Kayla Antosz and Carlson, \{Travis J.\} and Frens, \{Jeremy J.\} and Mark Biagi and Kufel, \{Wesley D.\} and Moore, \{William J.\} and Nicholas Mercuro and Raux, \{Brian R.\} and Rybak, \{Michael J.\}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2021",

month = dec,

day = "1",

doi = "10.1093/ofid/ofab554",

language = "English (US)",

volume = "8",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

AU - Rebold, Nicholas

AU - Morrisette, Taylor

AU - Lagnf, Abdalhamid M.

AU - Alosaimy, Sara

AU - Holger, Dana

AU - Barber, Katie

AU - Justo, Julie Ann

AU - Antosz, Kayla

AU - Carlson, Travis J.

AU - Frens, Jeremy J.

AU - Biagi, Mark

AU - Kufel, Wesley D.

AU - Moore, William J.

AU - Mercuro, Nicholas

AU - Raux, Brian R.

AU - Rybak, Michael J.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

AB - A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

KW - Pseudomonas aeruginosa

KW - carbapenem-resistant Enterobacterales

KW - imipenem-cilastatin-relebactam

KW - multidrug-resistant

UR - https://www.scopus.com/pages/publications/85124872379

UR - https://www.scopus.com/pages/publications/85124872379#tab=citedBy

U2 - 10.1093/ofid/ofab554

DO - 10.1093/ofid/ofab554

M3 - Article

AN - SCOPUS:85124872379

SN - 2328-8957

VL - 8

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 12

M1 - ofab554

ER -

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this